Targovax $TRVX.OL clinical phase oncolytic virus valued 35 mUSD
Targovax
CRNA
a clinical phase norwegian Biotech is currently at market cap NOK 327 million / 35 million USD.
Value inflection point very close as the company will need to raise funds in the very near future, which must either come from investors or from a possible partner deal.
PRESENTATION OF ONCOS-102 MELANOMA DATA AT SITC ANNUAL MEETING
https://www.healthcap.eu/presentation-of-oncos-102-melanoma-data-at-sitc-annual-meeting/
Q3 report:
https://www.targovax.com/en/event/q3-2019-targovax-quarterly-results/
Q3 transcript:
https://finance.yahoo.com/news/edited-transcript-trvx-ol-earnings-204325101.html
Value inflection point very close as the company will need to raise funds in the very near future, which must either come from investors or from a possible partner deal.
PRESENTATION OF ONCOS-102 MELANOMA DATA AT SITC ANNUAL MEETING
https://www.healthcap.eu/presentation-of-oncos-102-melanoma-data-at-sitc-annual-meeting/
Q3 report:
https://www.targovax.com/en/event/q3-2019-targovax-quarterly-results/
Q3 transcript:
https://finance.yahoo.com/news/edited-transcript-trvx-ol-earnings-204325101.html
